Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05315531 · ClinicalTrials.gov registry record · NA
The Effects of Hydration on Gut Health and Thinking
A NA study, sponsored by University of Illinois at Urbana-Champaign.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
NCT05315531: Completed NA study, sponsored by University of Illinois at Urbana-Champaign.
NCT05315531 is a NA study that has completed, run by University of Illinois at Urbana-Champaign. The registered enrollment target is 23 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05315531, a NA study, has completed, sponsored by University of Illinois at Urbana-Champaign.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
Study Summary
The central hypothesis is that improving hydration through increased water consumption will change the relative abundance of mucolytic bacteria found in the stool. Therefore the specific aims are 1) to quantify intervention effects on fecal microbiota relative abundance and plasma lipopolysaccharide binding protein, 2) observe the effects of the intervention on bowel frequency and signs/symptoms of gastrointestinal stress, and 3) to investigate relations between executive function and hydration status.
Primary Outcome
changes in the relative abundance of fecal microbiota
Interventions
- DIETARY_SUPPLEMENT Water Intake
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2021-08-23 |
| Est. Completion | 2022-07-29 |
| Phase | NA |
What the finished NCT05315531 record still lists
NCT05315531 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Water Intake is the first listed.
NCT05315531 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05315531 about?
NCT05315531 is a clinical study titled "The Effects of Hydration on Gut Health and Thinking". The central hypothesis is that improving hydration through increased water consumption will change the relative abundance of mucolytic bacteria found in the stool. Therefore the specific aims are 1) to quantify intervention effects on fecal microbiota relative abundance and plasma lipopolysaccharide...
What is the current status of trial NCT05315531?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2021-08-23. Estimated completion is 2022-07-29.
What interventions are being tested in trial NCT05315531?
The interventions under investigation include: Water Intake (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05315531?
This trial is sponsored by University of Illinois at Urbana-Champaign, which has 129 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05315531's enrollment target sits among peer trials
23 1755th of 2000 higher than 245 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI